dexcom G7

the most accurate CGM[1,2] powering AID systems



SEE WHY DEXCOM CGM IS THE CLEAR CHOICE FOR AUTOMATED INSULIN DELIVERY (AID) SYSTEMS

Patients have more options for managing their diabetes.

AID COMPATIBLE SENSORS

	dexcom G7	FreeStyle Libre 2 Plus
Warmup	30 min	1 hour
Share/Follow while using an AID system*	✓	✗
The only CGM with no fingersticks† from day 1	✓	✗
Urgent Low Soon and Delay 1st alerts: App features that help protect from severe hypoglycemia and diabetic ketoacidosis	✓	✗
Accuracy[1,2] in moments that matter most including:		
Most accurate[1,2] in hypoglycemia <70 mg/dL‡	✓	✗
Most accurate[1,2] in all rates of change in pediatrics§,[1,2]	✓	✗
Smallest CGM sensor currently powering AID systems	✓	✗
Connects to multiple AID pump brands	✓	✗

†Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

DEXCOM CGM POWERS THE MOST AID SYSTEMS CLINICALLY PROVEN TO IMPROVE GLYCEMIC OUTCOMES.[3,4]

DEXCOM HAS NEARLY 3X MORE PATIENTS PAYING $0 THAN FREESTYLE LIBRE‖

10+ YEARS OF PARTNERSHIPS

1 MIL+ CUSTOMER YEARS OF POWERING AID SYSTEMS[3]

Learn more at provider.dexcom.com/aid

*Separate Follow app and internet connection required. ‡Based on evaluation of %15/15 according to iCGM criteria. %15/15 is the proportion of the CGM system values that were within 15% of paired YSI values >70 mg/dL or ± 15 mg/dL of laboratory reference method values ≤ 70 mg/dL. §Freestyle Libre ages: 6-17, Dexcom ages:7-17. ‖Individual pricing may vary depending on insurance coverage. IQVIA FIA retail data, paid sensor claims from 1/1/2022 to 2/28/2023.

1 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf.
2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf.
3 Peacock S, et al. *Diabetes Ther.* 2023;14(5):839-855. 4 Dexcom, data on file, 2023.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.